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Hypoxia is a common feature in solid tumors and is associated with cancer progression. 
The main regulators of the hypoxic response are hypoxia-inducible transcription factors 
(HIFs) that guide the cellular adaptation to hypoxia by gene activation. The actual oxygen 
sensing is performed by HIF prolyl hydroxylases (PHDs) that under normoxic conditions 
mark the HIF-α subunit for degradation. Cancer progression is not regulated only by 
the cancer cells themselves but also by the whole tumor microenvironment, which 
consists of cellular and extracellular components. Hypoxic conditions also affect the 
stromal compartment, where stromal cells are in close contact with the cancer cells. The 
important function of HIF in cancer cells has been shown by many animal models and 
described in hundreds of reviews, but less in known about PHDs and even less PHDs in 
stromal cells. Here, we review hypoxic signaling in tumors, mainly in the tumor stroma, 
with a focus on HIFs and PHDs.
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iNTRODUCTiON
Solid tumors are most often partly hypoxic. During the rapid growth of cancer cells, the surround-
ing vasculature becomes inadequate and is unable to meet the high demand of oxygen creating 
heterogeneously distributed hypoxic areas within the tumor. Hypoxia in tumors promotes abnormal 
angiogenesis, desmoplasia, and inflammation. It also boosts the selection of cancer cells that have 
a more malignant phenotype promoting tumor progression and metastasis, and thereby serving 
as an indicator for disease outcome. Hypoxic tumor cells are also resistant to radiotherapy and 
most chemotherapies. Tumors include stromal cells and extracellular matrix (ECM) in addition to 
cancer cells, which are also affected by the hypoxic environment (1, 2). An ever-increasing number 
of studies have highlighted the importance of the tumor microenvironment (TME) in regulating 
tumor progression and dissemination (3).
The cellular response to the drop in oxygen concentration leads to stabilization of hypoxia-
inducible transcription factor (HIF) in all cell types, which is one of the key regulators of hypoxia 
response. The HIF prolyl hydroxylases (PHDs) are oxygen-dependent enzymes that target HIF 
for degradation in air. Thus, in hypoxia, PHDs are inactive, and HIF is stabilized. HIF regulates 
the expression of many genes that help cells to adapt to hypoxic conditions by decreasing oxygen 
consumption and increasing its supply. Generally, this includes shifting the energy metabolism to the 
less oxygen requiring glycolytic pathway and stimulation of the angiogenic genes to increase vascular 
flow to the hypoxic regions (4).
In addition to HIF activation, responses to hypoxia are also mediated through HIF-independent 
pathways. These signaling mechanisms include the unfolded protein response (UPR) and mam-
malian target of rapamycin (mTOR) signaling (5). They work as independent pathways, but in many 
cases, their signaling is integrated with HIF activation as well as with each other (6).
Unfolded protein response is activated during endoplasmic reticulum (ER) stress. ER stress 
arises from accumulation of unfolded proteins, which can be contributed by several factors such 
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as nutrient and calcium depletion and hypoxia. It consists of 
different and complex signal-transduction cascades, where 
pancreatic ER kinase (PERK), inositol-requiring enzyme 1, and 
activating transcription factor 6 act as sensor proteins, situated in 
the ER membrane. These mediate pro-survival signaling aiming 
to counteract ER stress by limiting the production of unfolded 
proteins and degrading the misfolded proteins preventing cel-
lular damage (5, 7). However, if UPR is not able to re-establish 
ER homeostasis, it can also lead to pro-death signaling leading 
to apoptosis. Many publications have shown UPR to be activated 
in numerous tumor types where hypoxia is one of the promoting 
factors. Cancer cells have, however, found ways to avoid the ER 
stress-induced apoptosis (7). UPR signaling has been shown to 
target vascular endothelial growth factor (VEGF) in cancer cells. 
Activation of transcription factor 4, which is downstream of the 
PERK, was shown to induce VEGF mRNA levels, but to lesser 
extent than HIF signaling. UPR was, nevertheless, also shown 
to phosphorylate HIF-1α enhancing its activity, which resulted 
in increased VEGF expression (8). URP signaling has also been 
shown to have a role in tumor infiltrating immune cells, which 
can promote both immunosurveillance and immune escape 
mechanisms (9).
The mTOR kinase is a part of the mTOR complexes 1 and 
2 (mTORC1 and 2), and it regulates cell survival, growth, and 
metabolism. mTOR mediates signals from different intracellular 
and extracellular stimuli such as growth factors, nutrients, stress, 
and oxygen levels (10). As a result, mTOR is phosphorylated at 
multiple sites, which in turn leads to direct phosphorylation of 
downstream targets such as eukaryotic translation initiation fac-
tor 4E binding protein 1 and ribosomal protein S6 kinase. Many of 
mTOR upstream signaling pathways go through the tumor sup-
pressor tuberous sclerosis 1 and 2 (TSC1/2) complex, and it is also 
subject to hypoxic regulation. TSC1/2 complex negatively regu-
lates the small GTPase ras-homolog-enriched-in-brain (Rheb). 
During mTOR activating signaling, TSC1/2 complex is inhibited 
by phosphorylation, leading to mTOR activation through active 
Rheb (6, 11). Hypoxia is known to increase the ratio of AMP/
ATP, which leads to activation of AMP-activated protein kinase 
(AMPK). AMPK is capable of phosphorylating TSC2, but this 
phosphorylation on the contrary activates the TSC1/2 complex, 
which inhibits Rheb. Inactive Rheb in turn cannot phosphoryl-
ate mTOR, which attenuates the downstream signaling (12). 
mTOR signaling also intercepts with HIF-dependent hypoxic 
signaling. HIF upregulates the expression of REDD1 (regulated in 
development and DNA damage responses), which also activates 
TSC1/2 complex decreasing mTOR signaling (13). However, 
this inhibitory mechanism seems to have cell type-dependent 
differences (14). Oncogenic mTOR has also been reported to 
promote HIF signaling as well as HIF target gene expression 
such as lysyl oxidase (LOX) (15) in an HIF-dependent way. VEGF, 
however, has been shown to be regulated by both HIF-dependent 
and HIF-independent mechanisms (16). This was also seen in 
cancer-associated fibroblasts (CAFs) isolated from human breast 
cancers where tumor suppressor p16INK4A downregulation led to 
increased Akt/mTOR signaling also affecting HIF-α positively 
and further increasing the VEGF-A secretion. Enhanced Akt/
mTOR signaling in CAFs was shown also to increase their 
invasion and migration capabilities. However, the role of HIF was 
not addressed (17).
Of these three different hypoxia response pathways men-
tioned, we will focus on the HIF signaling pathway that influ-
ences both cancer and stromal cells. Little is known about how 
HIF/PHDs activities regulate stromal cell function in the TME. 
Here, we review how HIF/PHD pathways impact on cancer 
progression in the different cellular and non-cellular compart-
ments of TME.
HiFs AND PHDs: KeY PLAYeRS iN 
OXYGeN SeNSiNG AND HYPOXiA 
SiGNALiNG
Hypoxic signaling is mediated via the hypoxia-inducible tran-
scription factor (HIF), which is a dimer consisting of two subunits, 
HIF-α and HIF-β. HIF-β (also known as ARNT) is constitutively 
expressed and stabile, but HIF-α is targeted to proteasomal 
degradation under normoxic conditions. Both subunits contain 
basic helix-loop-helix and PER-ARNT-SIM domains that are 
important for DNA binding and dimerization, but only HIF-α 
contains an oxygen-dependent degradation (ODD) domain 
that is important for the oxygen-dependent regulation. Under 
hypoxic conditions, HIF-α is able to bind with HIF-β forming 
a dimer that specifically binds to hypoxia response elements 
and so activates the transcription of over hundreds of genes that 
help the cells to adapt to low oxygen levels (18–21).
HIF-α has three different isoforms, HIF-1α, HIF-2α, and 
HIF-3α, of which the two first are more widely studied. HIF-1α 
and HIF-2α resemble each other, but the main differences are in 
their N-terminal transactivation domain (N-TAD). They both 
have a similar C-terminal transactivation domain (C-TAD), 
which contributes to the transcription of their shared targets, 
whereas the N-TAD differences confer the different binding 
capabilities and specificity among their targets (22). HIF-3α 
is the most different from the three and is subject to extensive 
alternative splicing resulting in many splicing variants. It has 
only one specific proline residue in the ODD domain and is 
lacking the C-TAD. Its function only as a transcription factor 
has been doubted and in fact different HIF-3α variants have 
been shown to have inductive and suppressive effects on HIF 
targets (23, 24).
The ODD domain contains two specific proline residues 
(Pro402 and 564 in human HIF-1α) that are hydroxylated 
under normoxic conditions by the HIF prolyl hydroxylase 1–3 
(also known as EGLN2, 1, and 3 or HIF-P4H1-3) (Figure  1). 
These enzymes belong to the 2-oxoglutarate (2-OG)-dependent 
dioxygenases and require oxygen, iron, ascorbate, and 2-OG for 
the hydroxylation reaction. The hydroxylated prolines act as rec-
ognition sites for the von Hippel-Lindau (pVHL)–E3 ubiquitin 
ligase complex, which tags HIF-α for proteasomal degradation 
(18, 25, 26). HIF is also regulated by factor-inhibiting HIF (FIH) 
in normoxia. FIH belongs to the same 2-OG family as PHDs. 
It hydroxylates the asparagine residue within the C-TAD block-
ing HIF from binding to the p300-CBP coactivators and inhibits 
the transcriptional activation of HIF (27).
FiGURe 1 | Regulation of HIF-α stabilization. Cellular oxygen levels are sensed by HIF prolyl hydroxylase (PHD) 1–3. They hydroxylate two specific proline residues  
in the HIF-α subunit, which require O2, Fe2+, and 2-oxoglutarate (2-OG). 4-Hydroxyprolines are recognized by von Hippel-Lindau (pVHL) complex that ubiquitylates 
HIF-α causing its proteasomal degradation. Another member of the dioxygenase superfamily, factor-inhibiting HIF (FIH), hydroxylates one asparaginyl residue at the 
transcriptional domain of HIF causing suppression of the transcriptional activity. Under hypoxic conditions, PHD and FIH activity is inhibited, and unhydroxylated 
HIF-α forms a complex with HIF-β and activates transcription of HIF target genes. Reactive oxygen species (ROS) and intracellular metabolites can inhibit PHDs  
and FIH-stimulating transcriptional activation of HIF-1α, leading to increased expression under normoxic conditions.
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HIF prolyl hydroxylases are fast in responding are fast in 
responding to changes in O2 concentration due to their much 
higher Km values than the physiological O2 concentrations (28). 
They are widely expressed in different tissues, but at varying 
levels. PHD2 is the main enzyme to regulate HIF. Inactivation of 
PHD2 alone leads to HIF stabilization in normoxia. Both PHD1 
and PHD3 are generally regarded to have a complementary role 
as inactivation of these alone does not lead to HIF stabilization 
(29). Global inactivation of PHDs in mice supports the finding 
that PHD2 is a key modulator in HIF regulation. Inactivation of 
PHD2 led to embryonic lethality, whereas phenotypes resulting 
from PHD1 or PHD3 inactivation were viable and grossly normal 
(30). PHDs have specificity toward different HIF-α hydroxyla-
tions. PHD2 preferentially hydroxylates HIF-1α, whereas PHD3 
has a preference toward HIF-2α (31). Both PHD2 and PHD3 
are hypoxia inducible, and it seems PHD2 is upregulated more 
by HIF-1 and PHD3 by HIF-2 (32). PHD2 has been reported to 
bind HIF-1α also in hypoxia inhibiting the HIF-1α N-terminal 
transcriptional activity without affecting its proteolysis (33).
HIF prolyl hydroxylases have been reported to have additional 
targets and to participate in HIF-independent signaling. PHD2 
has been shown to inhibit Akt by hydroxylation and binding 
of pVHL. As hypoxia inhibits PHD2, it activates and promotes 
tumor growth via Akt (34). PHD3 has been reported to interact 
with activating transcription factor-4, which has been shown to 
activate genes involved in redox balance, apoptosis, and general 
cell survival under conditions of compromised nutrition (35, 36). 
PHD3 has been associated with apoptosis via different media-
tors. For example, PHD3 induces a neuronal regulator kinesin 
family member 1B β (KIF1β) that in turn induces apoptosis. 
For this interaction, PHD3 hydroxylation activity was required, 
but it is still not known whether there is direct hydroxylation of 
KIF1β (37). PHD3 has been found to hydroxylate and activate 
the human homolog of the Caenorhabditis elegans biological 
clock protein CLK-2 (HCLK2), which is an important player 
in DNA damage response. This was required for the activation 
of the ATR/CHK1/p53 pathway, so that inhibition of PHD3 
attenuated DNA damage and the consequent apoptosis (38). 
PHD3 also directly inactivates the β2-adrenergic receptor 
(β2AR) by hydroxylating the intracellular domain, which leads 
to binding of the pVHL and subsequent degradation. β2AR 
activation is also known to play a role in apoptosis (39, 40).
HiF AND PHDs iN TUMORiGeNeSiS:  
BAD COPS?
Extensive literature exists regarding the role of HIF and PHDs 
expressed by tumor cells. We will only touch on a few aspects 
here, and we recommend more in-depth reviews such as Rankin 
et al. (41) and Schito and Semenza (4) for more detailed informa-
tion. Generally, HIF activation in cancer cells has been regarded 
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as tumor promoting. In solid tumors, this usually results from 
oxygen deprivation leading to hypoxia. However, HIF signaling 
can also be activated by other oncogenic or tumor suppressor 
pathways, but mutations directly affecting HIF activation are not 
common in cancer, with the exception of pVHL deficiency (42). 
As pVHL mediates the proteolysis of HIF-α subunits, inactivation 
of this protein leads to constitutively active HIF also in normoxic 
conditions. However, Von Hippel-Lindau mutations are respon-
sible only for a limited set of cancers such as clear cell renal cancer 
(ccRCC), pheochromocytoma, and pancreatic neuroendocrine 
tumors. HIF-2α has been shown to be the driving force in ccRCC 
(43). HIF activation can also be controlled through PI3K/PTEN/
AKT and RAS/RAF/MAPK signaling pathways. The former 
regulates the mTOR signaling that increases the translation of 
HIF protein, as described earlier. The latter has been reported 
to promote the HIF-coactivator p300 complex and subsequent 
transcription of target genes (42, 44, 45).
The metabolic components have also been shown to affect 
HIF stabilization through oxygen-independent regulation of 
PHD activity. The citric acid cycle (CAC) intermediate 2-OG 
is an absolute requirement for the enzymatic activity of PHD 
enzymes, whereas excess amount of other CAC metabolites 
fumarate, succinate, and oxaloacetate competitively inhibit PHDs 
(46). Inactivating mutations in enzymes processing fumarate 
and succinate leading to their accumulation, have been shown 
to induce HIF, and are associated with rare hereditary cancers, 
such as papillary renal cell carcinoma and paraganglioma 
(47–49). Mutations driving abnormal activation of isocitrate 
dehydrogenase (IDH) 3a were shown to decrease 2-OG amount 
causing HIF stabilization in cancer cells (50). Other types of IDH 
mutations lead to the production of 2-hydroxyglutarate (2-HG), 
which can competitively inhibit PHDs or even increase the activ-
ity depending on the 2-HG stereoisomerism (51, 52). However, 
the mechanisms for the PHD activation by 2-HG is debated (53). 
In triple negative breast cancer cells, the xCT glutamate-cystine 
antiporter has been shown to be inhibited by increased glutamate 
secretion. This in turn decreases the cellular cysteine level. Free 
cysteine prevents the oxidation of the specific cysteine residues in 
PHD2, but when the level decreases it leads to self-inactivation 
of PHD2 and subsequent HIF stabilization (54). Cancer cell-
secreted lactate from glycolysis was shown to stabilize HIF in 
tumor-associated macrophages (TAMs) leading to induction in 
VEGF and arginase 1 (ARG1), markers associated with an M2 
phenotype (55).
Multiple reports have showed that HIFs in cancer cells play 
a role in tumor progression. Inactivation of either HIF-1α or 
HIF-2α in in  vivo breast cancer cell models decreases tumor 
growth and metastasis to the axillary lymph nodes (56), lung 
(57–61), and bone (62, 63). Hypoxia promotes cancer cell sur-
vival in multiple different ways and these have been reviewed in 
many papers (64, 65) These ways include the switch to anaerobic 
metabolism and neovascularization, which will be discussed 
further below. Hypoxia also promotes growth factor signaling, 
epithelial–mesenchymal transition, decrease in the apoptotic 
potential and evasion from the immune system. Cancer cells 
secrete growth factors to promote their own growth and survival 
as they generally also have membrane receptors for these factors, 
resulting in autocrine signaling. These growth factors also 
stimulate the surrounding stromal cells to change into a tumor 
promoting phenotype (65). HIF-1 has been shown to directly 
inhibit apoptosis by decreasing for instance the expression of 
the proapoptotic Bcl-2 family protein Bid (66) and to induce the 
expression of the apoptosis inhibitor survivin (67). In this way, 
cancer cells are protected from the harsh hypoxic environment 
leading also to a decrease in drug responsiveness (66). Hypoxia 
also modifies the cell surface proteins, which can shield the cells 
from immune system in many ways. For example, HIF-1 has 
been shown to directly upregulate programmed death-ligand 1 
(PD-L1) (68) that suppresses T cell activation and CD47, which 
prevents phagocytosis by macrophages (69). HIF-1 induces a set 
of microRNAs that are small, non-coding RNA molecules known 
as hypoxamiRs (70). One of these is miR-210, which has been 
shown also to regulate cancer cell sensitivity toward cytotoxic 
T lymphocyte (CTL)-mediated lysis. miR-210 promotes cancer 
cell immune evasion without affecting cell surface proteins or 
CTL reactivity (71). In addition, HIF-induced miR-210 was 
shown also to promote angiogenesis. In cancer cells, miR-210 
inhibits the expression and secretion of fibroblast growth factor 
receptor-like 1, which in turn was found to be a negative regu-
lator of the angiogenesis (72).
In addition, hypoxia promotes cancer cell invasion and meta-
stasis. For example, hypoxia enhances the motility and invasive-
ness of the cancer cells by promoting epithelial to mesenchymal 
transition. This happens by upregulating the expression of the 
transcription factors Snail1, Snail2, and Twist that downregulate 
expression of E-cadherin that is an important component of 
the adherens junctions. HIF also mediates this indirectly via 
Notch signaling (59, 73). Generally, CAFs are responsible for 
the remodeling of the ECM that assists in cancer cell invasion. 
However, numerous publications have proved that hypoxia 
induces cancer cells to secrete ECM remodeling enzymes that 
have essential roles in invasion, metastasis and premetastatic 
niche formation (60, 74–80). HIF-1 also mediates expression 
levels of angiopoietin-like 4 and L1 cell adhesion molecule. The 
former hampers vascular permeability and the latter cancer cell 
adhesion to the vasculature. Both are needed in intravasation and 
extravasation during the metastatic process (57).
Hypoxia also promotes the cancer stem cell phenotype. These 
cells are capable of unlimited cell division, differentiation to other 
cell types and, most importantly, can initiate cancer (59, 81). 
The hostile hypoxic microenvironment in the primary tumor 
primes the cancer cells to survive in the metastatic organ. There 
is some evidence that hypoxia plays a role in setting a dormancy 
phenotype by upregulating the main dormancy genes (NR2F1, 
DEC2, and p27) in breast cancer cells, which persist post-hypoxia 
helping the cancer cells to become therapy resistance (82).
Experiments have also been performed targeting PHDs 
that regulate HIF stability. Cancer cell-specific PHD2 hap-
lodeficiency in the MMTV-PyMT breast cancer model led to 
increased HIF-1α and HIF-2α stabilization, but that did not 
have an effect on tumor growth or directly on the cancer cells’ 
invasive behavior. However, reduced lung metastasis was seen 
(83). In the MDA-MB-231 breast cancer model, PHD2 inactiva-
tion in cancer cells leads also to attenuate tumor growth. This 
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resulted from decreased transforming growth factor β (TGF-β) 
processing leading to decreased expression of the extracellular 
protein osteopontin (SPP1), which has been associated with 
breast cancer malignancy (84). However, opposing results have 
been reported with the MCF-7 breast cancer model where PHD2 
inactivation in cancer cells promoted tumor growth (84, 85) by 
upregulation of interleukin-8 (IL-8), VEGF, and the growth 
factor amphiregulin leading to increased vasculature forma-
tion (85). PHD2 inactivation led to HIF-1α stabilization and 
increased tumor growth in human colon carcinoma (HCT116), 
colorectal carcinoma (HT29 and RKO), and pancreatic carci-
noma (SU.86.86) models. Generally, this was due to increased 
number of blood vessels. Further experiments with HCT116 
cells revealed that the phenotype was not only HIF dependent. 
PHD2 was also shown to negatively regulate the transcription 
factor NF-κB. Hence, PHD2 inactivation led to increased 
secretion of angiogenic factors IL-8 and angiogenin (ANG) via 
NF-κB. These recruited bone marrow-derived cells (BMDCs) 
and promoted angiogenesis (86). PHD2 inactivation in murine 
osteosarcoma LM8, Lewis lung carcinoma (LLC), and B16BL6 
melanoma cell lines also decreased tumor growth in vivo. The 
effect was claimed to be mainly HIF-independent since inactiva-
tion of HIF-1α led to increase in the tumor growth, which could 
be abolished when HIF-1α was inactivated together with PHD2. 
After more validation in the LM8 cell line, the PHD2 inacti-
vation was shown to increase the number of vessels in the tumor 
but with decreased number of circulating cancer cells leading 
to reduced lung metastasis. LM8 cells were found to have 
increased expression of matrix metalloproteinases MMP2 
and MT1MMP, which increased TGF-β signaling leading to 
decreased cancer cell proliferation (87, 88). PHD2 overexpres-
sion in the pancreatic cancer cells MIA PaCa-2 and PANC-1 
decreased tumor growth by suppressing tumor vasculature in 
an HIF-dependent way resulting from decreases seen in VEGF 
and angiopoietin-1 (ANGPT1). However, this did not affect 
metastasis (89).
HIF prolyl hydroxylase 1 has been shown to play a role in 
cancer progression, but mainly in HIF-independent ways. PHD1 
inactivation in ZR75-1, T47D, and MCF7 breast carcinoma cell 
lines decreased the tumor growth in vivo by HIF independently 
decreasing the cyclin D levels that are involved in cell cycling 
processes (90). Later PHD1 was shown to hydroxylate Forkhead 
box O3 (FOXO3), which hampers its interaction with the USP9x 
deubiquitinase leading to degradation. Decrease in FOXO3a 
decreases the cyclin D levels (91). Inhibition of PHD1 in HCT116 
human colon carcinoma cells in  vitro sensitized the cells for 
chemotherapy by decreasing p53 activation during the treatment 
and inhibited DNA repair increasing cell death (92).
HiF AND PHDs iN TUMOR STROMA: 
GOOD COPS?
It has become more evident that cancer progression is not only 
regulated by the cancer cells but also by the surrounding cancer 
stroma (93). In addition to the cancer cells, the TME includes 
different cells such as CAFs, endothelial cells (ECs), immune 
cells, growth factors, cytokines, and ECM (94). As described 
earlier, HIF activation in cancer cells has generally been regarded 
as a tumor-promoting factor, but opposing results have been 
shown with stromal cells. Global PHD2 haplodeficiency leading 
to increased stromal HIF-1α and HIF-2α stabilization did not 
have an effect on primary tumor growth in LLC and pancreatic 
carcinoma tumor models as well as in the MMTV-PyMT breast 
cancer metastasis model. Surprisingly, PHD2 haplodeficiency led 
to decreased lung metastasis, and this clearly demonstrated the 
importance of stromal hypoxic signaling on tumor progression 
(83, 95). Recent publications show that stromal factors together 
regulate the growth and metastatic capabilities of the cancer cells 
in a complex manner, but nevertheless revealing possible insights 
into new therapeutic targets.
HYPOXiC ReSPONSe OF CAFs
Cancer cells are known to harness normal quiescent fibroblast 
to promote cancer progression and one way they achieve this is 
by secreting TGF-β. This activates the fibroblasts that become 
CAFs with increased capacity to contract and remodel the ECM 
(96). CAFs are the most abundant stromal cell type and are 
generally thought to promote cancer progression. Many cocul-
ture experiments with CAFs and cancer cells show increased 
tumor growth when compared with normal fibroblast together 
with cancer cells (97). CAFs can promote cancer cell invasion 
by secreting growth factors and cytokines or remodeling the 
ECM—either making tracks or aligning fibrils for cancer cells 
to travel along (98). When fibroblasts become CAFs, their 
gene expression changes, and one of the most commonly used 
marker for CAFs is α-smooth muscle actin (αSMA). In addition 
to αSMA, CAFs have been shown to express other markers such 
as fibroblast-specific protein 1 (FSP1), platelet-derived growth 
factor receptor (PDGFR), fibroblast activation protein, and 
periostin, for example. Recently, it has become clear that CAF 
populations are heterogeneous with diverse markers, which 
may give them specific functions during tumorigenesis (99).
HIF-1 has been shown to play a role in normal fibroblast 
and CAF behavior. One experiment showed HIF-1α as a tumor 
suppressor when its inactivation in FSP1-expressing cells in 
MMTV-PyMT transgenic mice led to enhanced tumor growth 
by reducing the tumor vascular density with less leaky vessels 
together with decreased infiltration of TAMs. The molecular 
mechanisms behind these results were not characterized. No dif-
ference was seen, however, in tumor growth in the same model 
with HIF-2α-deficient fibroblasts (100). Another experiment with 
in vitro data indicated that hypoxic CAFs are involved in forma-
tion of new blood vessels in a manner requiring both HIF-1α 
and G-protein estrogen receptor to upregulate VEGF in hypoxia 
(101). HIF-1α has been shown to work as a tumor promoting 
factor as well. Experiments using the active form of HIF-1α in 
human skin fibroblast showed increased tumor growth when co-
injected together with MDA-MB-231 cells, whereas HIF-2α did 
not have an effect. It was suggested that HIF-1α activation led to 
autophagy and aerobic glycolysis, which would produce nutrients 
to surrounding cancer cells promoting their growth (102, 103). 
PHD2 modulation in CAFs also affects tumor progression, but 
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mainly via HIF. Hypoxia, PHD2 depletion, or PHD2 haplodefi-
ciency was shown to inactivate CAFs by reducing their contrac-
tion and ECM remodeling capabilities (83, 104). Yes-associated 
protein 1 oncoprotein has been demonstrated to be important 
for CAF activation. It mediates the contraction via myosin light 
chain (MLC), which in turn regulates the contractile actomyosin 
function (105). Hypoxia and dimethyloxalylglycine (DMOG) 
decreased the levels of the phosphorylated MLC in CAFs (104). 
CAF inactivation was further demonstrated in vivo when CAFs 
with either PHD2 haplodeficiency or shRNA inactivation were 
orthotopically transplanted together with breast cancer cells 
leading to decreased lung metastases but without any changes in 
primary tumor growth (83, 104). Also, systemic PHD inhibition 
with DMOG decreased lung and liver metastases in a 4T1 breast 
cancer model. DMOG treatment also reduced the stiffness and 
αSMA levels within the tumors without affecting the number of 
αSMA positive cells (104). However, PHD2 haplodeficiency in 
platelet-derived growth factor receptor α (BDGFRα)-positive 
CAFs in MMTV-PyMT transgenic mice did not have an effect on 
the lung metastases (83). As a side note, targeting only one CAF 
marker might not ensure wide inactivation in a heterogeneous 
CAF population (99).
HYPOXiC ReSPONSe OF THe TUMOR 
vASCULATURe
The tumor vasculature is essential in supplying nutrients and 
oxygen to the fast dividing cancer cells but becomes quickly 
inadequate to meet the need of a fast expanding tumor. Oxygen 
deprivation in the tumor causes HIF stabilization and upregula-
tion of proangiogenic factors both from cancer cells and tumor 
stromal cells to promote the vessel formation needed for tumor 
progression and metastasis (106). ECM proteins have also been 
shown to be involved in angiogenesis. Hypoxia-inducible LOX 
promotes the expression of VEGF in cancer cells via PDGFRβ-
mediated Akt activation (107). Tumor vasculature, however, 
has been found to be abnormal with morphological changes, 
leakiness, and aberrant pericytes, which result in poorly perfused 
vessels that are not able to rescue the hypoxic condition. This 
results from excessively secreted pro- and antiangiogenic factors 
leading to disorganized vessel formation. This can hinder, for 
example, the delivery of anticancer drugs and also benefit cancer 
cells during their extravasation process (108).
Inactivation of HIF-1α in Tie2 positive ECs lead to decreased 
tumor growth in a subcutaneous LLC model, caused by reduced 
density of tumor vessels. ECs had decreased proliferation and 
migration under hypoxia as well as decreased expression levels 
of VEGF and VEGF receptor-1 (VEGFR-1). This demonstrated 
the importance of EC autocrine expression of these factors dur-
ing vessel formation (109). Similar results were obtained with 
the MMTV-PyMT breast cancer model and the LLC model. 
HIF-1α inactivation in Tie2-positive ECs drastically decreased 
lung metastasis, but only had moderate effect on primary 
tumor growth. In addition, HIF-1α inactivation decreased the 
expression of inducible nitric oxide synthase (iNOS), further 
decreasing the amount of nitric oxide (NO) and leading to less 
permeable ECs for cancer cell migration. HIF-2α inactivation 
in ECs on the other hand led to decreased levels of arginase 1 
(ARG1), which in turn increased the NO levels making the EC 
layer more accessible for cancer cells. Supporting this finding, 
in vivo tail vein injection of LLC cells showed more cancer cell 
colonization in the lung of HIF-2α EC null mice (110). However, 
HIF-2α inactivation from vascular endothelial (VE)-cadherin 
positive ECs decreased tumor growth in LLC and B16F1 models, 
as well as in carcinogen-induced skin epithelial tumors. HIF-2α 
inactivation was shown to increase the number of vessels and 
their branching but decreasing the number of mature functional 
tumor vessels. This resulted from disrupted delta-like ligand 
4/Notch (DII4/Notch) signaling leading to decreased expres-
sion of angiopoietin-2 (111, 112). These results show different 
roles for HIF-1 and HIF-2 in angiogenesis. Mice with PHD2 
haplodeficiency in Tie2-positive ECs did not have an effect on 
the primary tumor growth, but the amount of liver metastases 
in a pancreatic cancer model was reduced. This resulted from 
HIF-2-induced expression of sVEGFR-1 and VE cadherin that 
normalized ECs with less permeable vessels leading to a less 
hypoxic tumor without any changes in the actual number of 
vessels (83, 95).
Pericytes are mural cells that cover the ECs and provide 
vascular stability and are known to signal to each other during 
angiogenesis (108). Pericyte depletion was shown to disrupt 
primary tumor growth by decreasing the microvessel density and 
increasing hypoxia, but this, however, led to increased metastasis 
showing their importance in tumor vasculature (113). Later, the 
increased hypoxia was shown to induce Ang-2 expression within 
the tumor which resulted in vascular instability and lung metas-
tasis. This could be restored by inhibiting Ang-2 signaling (114).
HYPOXiC ReSPONSe OF iMMUNe CeLLS
The microenvironment of solid tumors also contains tumor infil-
trating immune cells. These include lymphoid cells and myeloid 
cells, such as T- and B-cells and natural killer cells, TAMs, mye-
loid-derived suppressor cells (MDSCs), and neutrophils, which 
all have both pro- and antitumorigenic effects. Hypoxia has been 
shown to alter immune resistance and suppression, which helps 
tumor cells to survive immune surveillance (2). TAMs are the 
most common immune cells found within the tumor and are 
generally associated with tumor progression and also have been 
shown to promote cancer cell invasion and angiogenesis (115). 
Hypoxic tumor regions have been shown to recruit TAMs via 
VEGF and semaphoring 3A expression and once in a low oxygen 
condition their gene expression profile changes to a more cancer 
promoting phenotype (116, 117). Macrophages are known to 
have plasticity, and their phenotype can change based on external 
cues. Once they get activated they can have tumor suppressing 
M1 or tumor promoting M2 polarization. Stimulation driving 
the M1 phenotype also activates HIF-1 which upregulates iNOS 
levels and drives NO synthesis. During M2 polarization HIF-2 
is induced leading to an increase in arginase-1, which in turn 
decreases the NO synthesis (118). In vitro assays suggest that 
depletion of HIF-1α in TAMs induces more M2 phenotype (119). 
By using PHD2-haplodeficient mice, which ensured less hypoxic 
tumors, Laoui et al. showed, however, that the oxygenation state in 
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the tumor did not significantly affect the differentiation of TAMs 
into M1 or M2 like (120). They saw changes in hypoxia-regulated 
genes in M2 like TAMs, but not in M1 like TAMs. Overall the 
results suggest that hypoxia itself does not influence the activa-
tion of the TAMs into M1 nor M2 (120).
HIF-1α- and HIF-2α-expressing macrophages have been 
shown to promote tumor progression. Inactivation of HIF-1α 
from lysozyme 2 (LysM)-positive neutrophils and macrophages 
in MMTV-PyMT mice led to hindered tumor progression and 
smaller tumors. This was shown to result from an increased 
number of cytotoxic T-cells (121). Mice lacking HIF-2α from 
LysM-positive macrophages in inducible hepatocellular car-
cinoma and colitis-associated cancer had reduced number of 
TAMs in tumor regions which associated with a delayed tumor 
progression tendency (122). However, opposing results have 
been shown with PHD inactivation. One experiment showed 
that PHD2 inactivation in macrophages together with CD4+ 
T-cells decreased the tumor progression by overall downregula-
tion of protumoral and antitumoral cytokines eventually leading 
to increased tumor cell death in an LLC model, and this was in 
part because of HIF-1α stabilization (123). Mice with a mela-
noma tumor model were treated with granulocyte–macrophage 
colony-stimulating factor together with systemic inhibition of 
PHD3 by AKB-6899 leading to decreased tumor size and lung 
metastasis. This resulted from HIF-2α stabilization in TAMs, 
which increased the expression of VEGF sequestering the 
soluble VEGFR-1 which decreased the vasculature within the 
tumor (124).
Hypoxia and HIF-1α stabilization regulates the MDSCs within 
the tumor enhancing their role as T-cell suppressors (125). 
Tumor-infiltrating MDSCs, as well as macrophages and tumor 
cells, were shown to have increased levels of the cell surface 
protein PD-L1, which was shown to be an HIF-1α target and 
upregulated by hypoxia. PD-L1 upregulation in MDSCs sup-
pressed T-cell activation, whereas PD-L1 blockade under hypoxia 
enhanced MDSC-mediated T-cell proliferation and function and 
was associated with decreased interleukin-6 and interleukin-10 
expression (68). Hypoxia has been shown to decrease the expres-
sion of the cell surface protein major histocompatibility complex 
class I in vivo and in vitro in renal cell carcinoma cells providing 
them a mechanism to evade immune surveillance by cytotoxic 
T-cells (126).
HYPOXiC ReSPONSe OF THe eCM
In addition to the different cell types within the TME, the ECM 
composition and structure also contributes to tumor progres-
sion (94). The ECM does not only provide an architectural 
scaffold defining tissue boundaries but it also regulates cellular 
behavior, such as cell adhesion and migration by mechanical 
and biochemical cues. The ECM can bind and store growth 
factors or directly interact with receptors on the cell surfaces. 
The ECM is a dynamic meshwork of proteins that is constantly 
being remodeled and it is rich in proteoglycans and fibrillar col-
lagens. ECM proteins have also been shown to directly induce 
cancer cell proliferation and metastasis. LOX is upregulated by 
hypoxia, and in a colorectal cancer model, LOX induced cancer 
progression via activation of SRC signaling (127). The ECM 
is mainly secreted by CAFs as it is one of the main functions 
of fibroblast to maintain the homeostasis of the ECM. CAFs, 
however, have abnormal ECM regulation activity, and they 
have been shown to secrete more ECM proteins than normal 
fibroblasts (98). In addition to CAFs, cancer cells are known to 
play a part in ECM remodeling (128). A high collagen content 
together with a stiff ECM is generally associated with malignant 
metastatic cancers (75, 129). The biosynthesis of the fibrillar 
collagens requires posttranslational modifications that take 
place both inside and outside the cell with the help of collagen 
modifying enzymes, many of which are known to be regulated 
by HIF (130). Collagen modifying enzymes have been shown to 
have important roles in cancer progression. Inactivation of col-
lagen prolyl 4-hydroxylase P4HA1 or P4HA2 in MDA-MB-123 
breast cancer cells decreased collagen deposition and attenuated 
tumor growth and resulted in as much as 99% decrease in lung 
metastasis (79). Inactivation of lysyl hydroxylase PLOD2 in the 
same cancer model decreased the metastasis to lungs resulting 
from inefficient formation of collagen fibers and decreased 
tumor stiffness (78). Inhibiting LOX and lysyl oxidase-like 2 
(LOXL2) and LOXL4 decreased metastasis in several cancer 
cell types (60, 74, 76). LOX, LOXL2, and LOXL4 deficiencies 
decreased collagen cross-linking and stiffness which was also 
needed to recruit CD11b+ BMDCs into the premetastatic niches 
to promote tumor cell colonization (60, 77, 80). LOXL2 in turn 
upregulated the expression of matrix remodeling enzymes such 
as tissue inhibitor of metalloproteinase-1 and matrix metal-
loproteinase-9 (MMP9) (76). LOXL2 also activated CAFs via 
integrin β3 and promoted their collagen contraction, a pheno-
menon known to increase matrix stiffness (131).
Cancer-associated fibroblasts are able to mechanically remodel 
the ECM by active contraction resulting in matrix stiffening 
(105). CAFs with PHD2 haplodeficiency were less active than 
wild-type CAFs which was demonstrated by decreased expres-
sion levels of markers associated with CAFs (αSMA, FSP1, and 
PDGFRα) and decreased contraction capabilities (83). PHD2 
haplodeficiency in CAFs also decreased matrix production, and 
this was accompanied by decreased expression of collagen modi-
fying enzymes LOX, P4HA1, P4HA2, PLOD2 as well as matrix 
metalloproteinases MMP2 and MMP9. This is partly surprising, 
since hypoxic fibroblast and cancer cells generally upregulate 
the expression of the same genes (132). Similar results were seen 
with human head and neck carcinoma-associated fibroblasts and 
human vulvar carcinoma-associated fibroblasts. PHD2 inactiva-
tion or 1% oxygen decreased αSMA expression, and they had 
decreased contraction capabilities (104).
HYPOXiC ReSPONSe OF CANCeR 
MeTABOLiSM
One of the most common characteristics for cancer cells is rapid 
proliferation, which is accompanied by high demands of energy. 
In normoxia, cells generally produce energy as ATP by mito-
chondrial oxidative phosphorylation, which is an O2-dependent 
pathway. As tumors grow, cells face the limitation of decreased 
FiGURe 2 | Hypoxia affects the tumor microenvironment. Hypoxia arises due to rapidly proliferating cancer cells with inadequate vasculature. The excessive 
angiogenic signaling promotes formation of abnormal leaky vasculature with a decreased amount of pericytes. Hypoxia promotes tumor-associated macrophage 
(TAM) infiltration, which support tumor growth. Hypoxic cancer cells corrupt fibroblasts by secreting, for example, transforming growth factor β, which turns 
fibroblast into cancer-associated fibroblasts (CAFs) to drive the cancer progression. CAFs promote desomplasia and together with cancer cells they secrete 
extracellular matrix (ECM) components such as collagens. One important secreted factor is the hypoxia-inducible enzyme lysyl oxidase, which cross-links fibrillar 
collagen at the primary tumor and prepares the premetastatic niche for the recruitment of bone marrow derived cells (BMDCs) that are needed for cancer cell 
colonization at the metastatic site.
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oxygen concentration and switch to inefficient glycolysis to ensure 
ATP production (46). HIF-1 has been shown to be an important 
regulator in the metabolic switch as it induces the expression of 
genes that adjust the cellular metabolism away from oxidative 
phosphorylation toward increased glycolysis. This mechanism 
is not just to ensure the ATP production under hypoxia but also 
to prevent excessive formation of reactive oxygen species (ROS). 
Most importantly HIF-1 induces pyruvate dehydrogenase 
kinase 1 that inhibits the activity of the pyruvate dehydrogenase 
complex (PDC). PDC regulates the first step needed in oxidative 
phosphorylation where pyruvate is converted to acetyl coenzyme 
A (133). HIF-1α also upregulates lactate dehydrogenase A and 
monocarboxylate transporter 4 which promotes conversion of 
pyruvate to lactate (end product of glycolysis) and transports 
it out of the cell, respectively (134, 135). HIF activation also 
upregulates the expression of glucose transporters GLUT1 
and GLUT3, which are responsible for the glucose import into 
the cells (136, 137). Lactate from glycolysis is considered as a 
major reason for the tumor acidification. Hypoxia upregulates 
carbonic anhydrase IX, which regulates the tumor pH and has an 
important role in the survival of tumor cells in hypoxic regions of 
tumors and metastasis (138). In addition, HIF indirectly targets 
the metabolic genes that contribute to the glycolytic shift by 
upregulating miR-210. miR-210 in turn inhibits multiple targets 
such as iron-sulfur cluster assembly proteins (ISCU), cytochrome 
c oxidase assembly protein (COX10), NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex 4 (NDUFA4), and succinate 
dehydrogenase complex subunit D (SDHD), all of which play 
a role in mitochondrial function (139–141). PHD3 was in 
turn shown to induce the activity of PDC HIF independently 
by binding to the complex. PHD3 deficient cells were seen to 
have clear decreased PDC activity, which promoted survival in 
prolonged hypoxia together with a lower amount of ROS (142). 
HIF also suppresses mitochondrial function by downregulating 
multiple components in the electron transport chain and also 
by direct mitochondrial autophagy mediated by increased BCL2 
interacting protein 3 (BNIP3) levels. In this way, hypoxia also 
decreases the levels of ROS, which are harmful in increased 
quantities (143). There are reports stating that mitochondrial 
ROS itself also regulates HIF, but there is also many opposing 
results [reviewed in Ref. (144)]. Increased ROS levels have been 
shown to promote HIF stabilization during hypoxia, by further 
inhibiting PHD enzymes. Contradicting results claim it is not 
ROS regulating HIF stabilization, but rather the mitochondria, 
which monitor the intracellular oxygen availability. Under 
normoxic conditions ROS are able to stabilize HIF, but the exact 
mechanism is not clear. It has been suggested to be via inhibi-
tion of PHDs or pVHL, but another signaling pathway has been 
proposed. HIF-1α gene expression was shown to be upregulated 
in oral squamous cell carcinoma and MCF-7 breast cancer cells 
by ROS via induced ERK and P13K/AKT signaling (145, 146). 
Overall, HIF-regulated glucose metabolism supplies sufficient 
glucose import for less efficient glycolysis and removes the excess 
end products out of the cell. It defends the cells against increased 
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ROS production, which is generated in the oxidative phospho-
rylation pathway under too low oxygen concentration and gives 
the cancer cells protection to proliferate and grow under hypoxic 
conditions (147).
Within the solid tumor there are regions that are not under 
hypoxia, but still the cancer cells have a tendency to switch to inef-
ficient glycolysis even in presence of oxygen. However, the meta-
bolic state in the different cells within the tumor is heterogeneous 
and there has been evidence of supplying metabolites between 
cells (148). When fibroblasts become CAFs, they have been 
shown to decrease the expression of isocitrate dehydrogenase 
3α. This leads to a decreased amount of effective 2-oxoglutarate, 
which is needed as a co-substrate in the hydroxylation reaction, 
and increasing levels of succinate and fumarate. This results to 
PHD inhibition, which stabilizes HIF-1α and promotes glycolysis 
in the CAFs. Metabolites from the normoxic glycolysis in CAFs 
was hypothesized to feed the surrounding cancer cells (149).
CONCLUSiON AND FUTURe 
PeRSPeCTiveS
Hypoxia is a condition that plays a role in normal physiology, 
such as during embryonic development, but it is more commonly 
associated with pathological states. Oxygen deprivation is a com-
mon feature of all solid tumors and affects all components of the 
TME (Figure 2). Hypoxia has clear effects on both cancer cells 
and surrounding stromal cells, but it does not promote tumor 
progression in every case. Different cell types seem to be differen-
tially regulated by the hypoxic environment. In cancer cells, HIF 
stabilization generally promotes tumor progression. Inactivation 
of HIF-1 or HIF-2 in cancer cells in mouse cancer models 
decreases the tumor growth and the formation of metastases 
in many ways, practically affecting all the hallmarks of cancer. 
When cancer cells are targeted with PHD2 inactivation, which 
enables HIF stabilization, the results are more variable. PHD 
enzymes do also have HIF-independent targets and functions 
that can complicate their role in cancer promotion. However, 
PHD2 haplodeficiency in ECs leads to less tumor hypoxia result-
ing from HIF-2 activation in the ECs themselves stimulating EC 
intrinsic proangiogenic signaling leading to EC normalization. 
Global haplodeficient inactivation of PHD2 or treatment with a 
PHD inhibitor does not have an effect on primary tumor growth, 
but it rather decreases metastasis. Targeting PHD2 in CAFs leads 
to their deactivation and reduces their capabilities to promote 
cancer cell invasion and metastasis both in vitro and in vivo. These 
findings suggest that global targeting of PHD and HIF activities 
is sufficient to reprogramme the TME to suppress tumor progres-
sion. However, we are only beginning to understand how hypoxia, 
HIFs and PHDs alter the TME, and further research is required 
to gain insight. Thus, while hypoxia research has been performed 
for decades, recent data suggests that there is much more to learn, 
and that this may have important clinical implications regarding 
the use of agents that target hypoxia pathways such as HIF or 
PHD inhibitors.
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